Advertisement
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Greene RT. Coccidioidomycosis and paracoccidioidomycosis. In: Greene CE, ed. Infectious Diseases of the Dog and Cat. 4th ed. Elsevier; 2012:634–645.
-
2.
Shubitz LF, Dial SM. Coccidioidomycosis: a diagnostic challenge. Clin Tech Small Anim Pract. 2005;20(4):220–226. doi:10.1053/j.ctsap.2005.07.002
-
3.
Clemons KV, Laniado-Laborin R, Stevens DA. Comparative aspects of coccidioidomycosis in animals and humans. In: Proceedings of the Sixth International Symposium on Coccidioidomycosis. New York Academy of Sciences; 2007:395–403.
-
4.
Graupmann-Kuzma A, Valentine BA, Shubitz LF, Dial SM, Watrous B, Tornquist SJ. Coccidioidomycosis in dogs and cats: a review. J Am Anim Hosp Assoc. 2008;44(5):226–235.
-
5.
Davidson AP, Shubitz LF, Alcott CJ, Sykes JE. Selected clinical features of coccidioidomycosis in dogs. Med Mycol. 2019;57(suppl 1):S67–S75.
-
6.
Galgiani JN, Catanzaro A, Cloud GA, et al. Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis. Ann Intern Med. 2000;133(9):676–686.
-
7.
Johnson LR, Herrgesell EJ, Davidson AP, Pappagianis D. Clinical, clinicopathologic, and radiographic findings in dogs with coccidioidomycosis: 24 cases (1995–2000). J Am Vet Med Assoc. 2003;222(4):461–466.
-
8.
Sykes JE. Coccidioidomycosis. In: Ettinger SJ, Feldman EC, Côté E, eds. Textbook of Veterinary Internal Medicine. 8th ed. Elsevier; 2017:1024–1027.
-
9.
Shubitz LF, Schlacks S, Vishkautsan P, Butkiewicz CD, Worthing KA. Posaconazole treatment for refractory coccidioidomycosis in dogs (Erratum in J Vet Intern Med. 2022;36[2]:837). J Vet Intern Med. 2021;35(6):2772–2777. doi:10.1111/jvim.16282
-
10.
Catanzaro A, Galgiani JN, Levine BE, et al. Fluconazole in the treatment of chronic pulmonary and nonmeningeal disseminated coccidioidomycosis. Am J Med. 1995;98(3):249–256.
-
11.
Graybill JR, Stevens DA, Galgiani JN, Dismukes WE, Cloud GA. Itraconazole treatment of coccidioidomycosis. Am J Med. 1990;89(3):282–290.
-
12.
Tucker RM, Denning DW, Arathoon EG, Rinaldi MG, Stevens DA. Itraconazole therapy for nonmeningeal coccidioidomycosis: clinical and laboratory observations. J Am Acad Dermatol. 1990;23(3 pt 2):593–601.
-
13.
Pappagianis D, Zimmer BL. Serology of coccidioidomycosis. Clin Microbiol Rev. 1990;3(3):247–268.
-
14.
Smith CE, Saito MT, Simons SA. Pattern of 39,500 serologic tests in coccidioidomycosis. J Am Med Assoc. 1956;160(7):546–552.
-
15.
Boothe DM. Treatment of fungal infections. In: Boothe DM, ed. Small Animal Clinical Pharmacology and Therapeutics. 2nd ed. Elsevier; 2012:364–397.
-
16.
Mazepa ASW, Trepanier LA, Foy DS. Retrospective comparison of the efficacy of fluconazole or itraconazole for the treatment of systemic blastomycosis in dogs. J Vet Intern Med. 2011;25(3):440–445.
-
17.
Crabtree AC, Keith DG, Diamond HL. Relationship between radiographic hilar lymphadenopathy and serologic titers for Coccidioides sp. in dogs in an endemic region. Vet Radiol Ultrasound. 2008;49(6):501–503.
Advertisement
Retrospective evaluation of the efficacy of fluconazole for the treatment of coccidioidomycosis in dogs: 49 cases (2015–2020)
Abstract
OBJECTIVE
To characterize the clinical course and therapeutic response in dogs with coccidioidomycosis treated with fluconazole.
ANIMALS
49 client-owned dogs with coccidioidomycosis that were treated with fluconazole and had ≥ 2 follow-up examinations.
PROCEDURES
Medical records were retrospectively searched to identify dogs in which coccidioidomycosis was diagnosed between January 2015 and May 2020. Data recorded from each dog included signalment, clinical signs, diagnostic test results, and treatment.
RESULTS
Dogs were treated with fluconazole at a median initial dosage of 19.7 mg/kg/d. Median treatment duration was 298.5 days, with 26 of the 49 dogs completing treatment during the study period. Respiratory signs, lethargy, and hyporexia were the most common clinical signs. Frequency of lethargy decreased after 30 days, whereas frequency of hyporexia and respiratory signs decreased after 90 days. Median IgG titer at diagnosis was 1:32 and was significantly decreased, compared with baseline titer, at all recheck intervals after 90 days. Hyperglobulinemia, monocytosis, and neutrophilia were the most common clinicopathologic abnormalities. Hyperglobulinemia resolved within 30 days, neutrophilia resolved within 90 days, and monocytosis resolved after 180 days.
CLINICAL RELEVANCE
Improvements in clinical signs, titers, and clinicopathologic abnormalities were observed after initiation of treatment with fluconazole. Improvement began as early as the first 3 months of treatment, but some variables did not resolve until after 6 to 9 months of treatment. This information provides clinical guidance and describes expectations when prescribing fluconazole to treat coccidioidomycosis in dogs.
Contributor Notes
Powered by PubFactory